Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7
Lilly's performance-based plans for Trulicity may be harder to sustain if Novo's competing once-weekly GLP-1 agonist semaglutide is approved in December, following superiority in a head-to-head diabetes study.
You may also be interested in...
Novo's oral GLP-1 receptor agonist has a lot going for it in diabetes based on the latest data, but still needs to prove cardiovascular benefit; a new large outcomes study is now in the works.
Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.
Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).